Renaissance Lakewood, LLC: A Premier Pharmaceutical Contract Development and Manufacturing Organisation

Renaissance Lakewood, LLC is a leading global contract development and manufacturing organisation (CDMO) specialising in nasal and sterile injectable dosage forms.

Established in 1979, Renaissance has evolved into a trusted partner for pharmaceutical companies worldwide. With a state-of-the-art facility in Lakewood, New Jersey, the company offers comprehensive bench-to-shelf services, ensuring seamless transitions from development to commercialisation. Their commitment to quality and innovation has solidified their reputation in the industry.

Key Products and Services:

• Nasal Spray Manufacturing: Renaissance provides extensive capabilities in producing unit-dose, bi-dose, and multi-dose nasal sprays. Their advanced laboratories and nearly two decades of experience make them a one-stop solution for formulation, development, testing, and commercialisation of nasal spray products.

• Aseptic Filling: The company boasts decades of expertise in the development and aseptic filling of sterile injectable products. Their modern facilities support a wide range of sterile injectable programmes, from development stages to full-scale commercial manufacturing.

• Research & Development: Renaissance’s recently expanded R&D laboratory is equipped to meet diverse project deadlines and development objectives. They cater to various clients, from small virtual groups to large global enterprises, providing world-class service and support.

• Packaging Services: Offering a variety of secondary packaging solutions, Renaissance ensures that manufactured products are packaged accurately and according to specifications. Their packaging lines are equipped with multiple vision systems to maintain high-quality standards.

In September 2024, Renaissance completed a significant campus enhancement project, unveiling a new 67,000-square-foot warehouse at their headquarters. This expansion underscores their dedication to technological advancement and increased capacity, reinforcing their position as a premier CDMO in the pharmaceutical sector.